Drugs / DSP-0337
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03416816 | May 2018 → Jun 2020 | neoplasm | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-0337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416816 ↗ |
| Route | Oral | “orally administered DSP-0337” NCT03416816 ↗ |